

2020 年 抗癌藥物指引版本對照

肝癌

異動 Regimen	2019 版	2020 版
Ramucirumab	—	○
Pembrolizumab	—	○
Atezolizumab + Bevacizumab	—	○

大腸直腸癌-無異動

肺癌

異動 Regimen	2019 版	2020 版
Small Cell Lung Cancer / Primary or Adjuvant Therapy / Extensive Stage		
● Atezolizumab + Carboplatin + Etoposide	—	○
Small Cell Lung Cancer / Subsequent Chemotherapy		
● Pembrolizumab	—	○
Non-Small Cell Lung Cancer / Chemotherapy Regimens Used with Radiation Therapy / Consolidation Therapy		
● Durvalumab		
Non-Small Cell Lung Cancer / Target Therapy / ALK positive		
● Alectinib		
● Ceritinib		
● Brigatinib		
● Lorlatinib		
Non-Small Cell Lung Cancer / Target Therapy / ROS1 positive		
● Crizotinib		
● Ceritinib		

婦癌

異動 Regimen	2019 版	2020 版
Ovarian Cancer / Acceptable Recurrence Therapies / 1st line therapy / Platinum-Sensitive Disease		
● Bevacizumab + Lipo-Doxorubicin + Carboplatin	—	○

乳癌

異動 Regimen	2019 版	2020 版
Adjuvant / Neoadjuvant Therapy (HER2-POSTIVE)		
● Trastuzumab + Pertuzumab	—	○
● T-DM1	—	○
● Paclitaxel + Trastuzumab	Preferred	Other
Adjuvant / Neoadjuvant Therapy (HER2-NEGATIVE)		
● Capecitabine	—	○
● Carboplatin + Docetaxel (Triple negative)	—	○
Recurrent or Metastatic Breast Cancer / HER2-NEGATIVE		
● Talazoparib	—	○
● Carboplatin + Docetaxel (Triple negative)	—	○
● Atezolizumab + albumin-bound paclitaxel	—	○
● Carboplatin	Other	Preferred
● Cisplatin	Other	Preferred
Endocrine Therapy / Recurrent or Metastatic Breast Cancer / Postmenopausal		
● Ribociclib + Exemestane	—	○
● Abemaciclib + Letrozole	—	○
● Abemaciclib + Anastrozole	—	○
● Abemaciclib + Exemestane	—	○
● Abemaciclib + Fulvestrant	—	○
● Alpelisib + Fulvestrant	—	○

● Ribociclib + Tamoxifen	—	○
● Abemaciclib	—	○

胃癌

異動 Regimen	2019 版	2020 版
Preoperative Chemoradiation Therapy		
● Cisplatin + 5 Fu (100/1000)	Other	Preferred
● Cisplatin + 5 Fu (15/800)	Other	Preferred
● Cisplatin + Capecitabine	Other	Preferred
● Paclitaxel + 5 Fu	Other	Preferred
● Paclitaxel + Carboplatin	Preferred	Other
Postoperative Chemotherapy		
● Docetaxel + TS 1	—	○

泌尿道癌-無異動

頭頸癌

異動 Regimen	2019 版	2020 版
Head And Neck Cancers / Systemic Therapy + Concurrent Radiotherapy		
● Cetuximab + Cisplatin	○	—
Head And Neck Cancers / Postoperative Chemoradiation Therapy		
● Cisplatin + 5 FU	○	—
Head And Neck Cancers / Recurrent, Unresectable, or Metastatic Regimens / Immunotherapy		
● Pembrolizumab + Cisplatin + 5 FU	—	○
● Pembrolizumab + Carboplatin + 5 FU	—	○
● Pembrolizumab	—	○

Nasopharynx Carcinoma / Recurrent, Unresectable, or Metastatic (incurable) Regimens		
● Cisplatin + Gemcitabine	Other	Preferred
● Cisplatin + Docetaxel	○	—

淋巴癌

異動 Regimen	2019 版	2020 版
Hodgkin Lymphoma (Age ≥18 years) / Systemic therapy for relapsed or refractory disease / Second-Line or Subsequent Therapy Options / CHL		
● Brentuximab vedotin + Bendamustine	—	○
● Brentuximab vedotin + Nivolumab	—	○
Hodgkin Lymphoma (Age ≥18 years) / Systemic therapy for relapsed or refractory disease / Second-Line or Subsequent Therapy Options / NLPHL		
● ± Retuximab (DHAP)	-	±
● ± Retuximab (ESHAP)	-	±
● ± Retuximab (ICE)	-	±
● ± Retuximab (IGEV)	-	±
Non-Hodgkin's Lymphoma / Diffuse Large B-Cell Lymphoma / Second-line Therapy (non-candidates for high-dose therapy)		
● ± Rituximab (Bendamustine)	+	±

食道癌-無異動

膽管癌-新增

Regimen
Intrahepatic or Extrahepatic Cholangiocarcinoma / Post resection (R0, R1)
● Capecitabine
Intrahepatic or Extrahepatic Cholangiocarcinoma / Gemcitabine-based chemotherapy followed by fluoropyrimidine-based chemoradiation
● Gemcitabine+Capecitabine
Intrahepatic or Extrahepatic Cholangiocarcinoma / Unresectable / Metastatic disease
● Gemcitabine + Cisplatin
● Gemcitabine + Oxaliplatin
● Oxaliplatin + Capecitabine
● Cisplatin + 5 Fu
● Pembrolizumab
● Nivolumab

胰臟癌-新增

Regimen
Pancreatic Cancer / Neoadjuvant Chemotherapy
● FOLFIRINOX
● Modified FOLFIRINOX
● Gemcitabine + nab-Paclitaxel
● Gemcitabine + Cisplatin (for known BRCA 1/2 or PALB2 mutation)
Pancreatic Cancer / Adjuvant Chemotherapy
● Modified FOLFIRINOX
● Gemcitabine + Capecitabine
● Gemcitabine

<ul style="list-style-type: none"> ● 5 Fu + Leucovorin
Pancreatic Cancer / Locally Advanced or Metastetic Disease / Good PS
<ul style="list-style-type: none"> ● FOLFIRINOX
<ul style="list-style-type: none"> ● Modified FOLFIRINOX
<ul style="list-style-type: none"> ● Gemcitabine + nab-Paclitaxel
<ul style="list-style-type: none"> ● Gemcitabine + Cisplatin (for known BRCA 1/2 or PALB2 mutation)
<ul style="list-style-type: none"> ● Gemcitabine + Erlotinib
<ul style="list-style-type: none"> ● Gemcitabine
<ul style="list-style-type: none"> ● GOLF
<ul style="list-style-type: none"> ● TS-1
Pancreatic Cancer / Locally Advanced or Metastetic Disease / Poor PS
<ul style="list-style-type: none"> ● Gemcitabine
<ul style="list-style-type: none"> ● Gemcitabine (fix-dose-rate)
Pancreatic Cancer / Metastetic, Useful in Certain Circumstances
<ul style="list-style-type: none"> ● Pembrolizumab